Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

1(100.0%)

1Total

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT01297465Phase 3Completed

PERgoveriS In Stratified Treatment for Assisted Reproductive Technique

Role: collaborator

NCT01363674Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Greece

Role: collaborator

NCT01080027Completed

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)

Role: collaborator

NCT01112345Completed

An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters

Role: collaborator

All 4 trials loaded